Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase 2a basket study. An ongoing phase 2a study is proving ...

For the first time since he was fired as CEO in June, Arthur T. Demoulas parked at Market Basket's headquarters in Tewksbury Thursday morning and began his workday. Hundreds of workers greeted him, ...